| Trial ID: | L5491 |
| Source ID: | NCT05347459
|
| Associated Drug: |
Dapagliflozin
|
| Title: |
Cognitive Protective Effect of Newer Antidiabetic Drugs
|
| Acronym: |
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes
|
| Interventions: |
DRUG: Dapagliflozin|DRUG: Empagliflozin|DRUG: Canagliflozin|DRUG: Sitagliptin|DRUG: Saxagliptin|DRUG: Linagliptin|DRUG: Vildagliptin
|
| Outcome Measures: |
Primary: Prevention of decline in cognitive function associated with type 2 diabetes, Slowed reduction of the Montreal Cognitive Assessment Battery Score, 1 Year | Secondary: Better cognitive performance in the intervention group at baseline, Higher Montreal Cognitive Assessment Battery Score, 1 Year | Other: Reduced serum inflammatory markers in intervention group, 1 Year
|
| Sponsor/Collaborators: |
Sponsor: Alexandria University
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
100
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2022-03-02
|
| Completion Date: |
2023-12
|
| Results First Posted: |
|
| Last Update Posted: |
2022-07-26
|
| Locations: |
Alexandria University, Alexandria, Egypt
|
| URL: |
https://clinicaltrials.gov/show/NCT05347459
|
